Criteria
| Eligible Active Ingredient: | Cimetidine. As an oral preparation |
| With Effective From: | 10-Nov-1995 |
| Indication Permitted: | (a) Short-term relief of heartburn, dyspepsia and hyperacidity and (b) Prophylactic management of nocturnal heartburn. |
| Maximum Daily Dose: | (a) 200 mg and (b) 100 mg (as a single night-time dose). |
| Maximum Supply per Transaction: | 14 days |
| Minimum Age of User: | |
| Patient Information Leaflet from HSA/PSS: | Download PIL (Link to HSA website) |
Mechanism of Action of Cimetidine
Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.
Additional Information of Cimetidine
| Pharmacology Class: | Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) |
| Therapeutic Class: | Drugs For Acid Related Disorders |
| Chemical Class: | H2-Receptor Antagonists |
| Synonyms: | 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine | 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine | Cimetag | Cimetidin | Cimetidina | Cim√©tidine | Cimetidinum | N-Cyano-n’-methyl-n”-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine | N”-cyano-N-methyl-n’-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine | Tagamet hb 200 | Ulcerfen |
Show All HSA-registered therapeutic products granted exemption to supply without prescription
References
HSA-Registered Products Containing Cimetidine As an oral preparation
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.